AutoIVF secures investment to transform fertility care with automated egg retrieval system

Fertility tech company AutoIVF has secured new equity funding in a round led by Vitrolife Group, with support from Alpha Edison and IVF specialists.

The company’s lead product, OvaReady, automates egg retrieval and preparation, aiming to shift parts of the IVF process outside traditional lab settings.

With infertility affecting one in six people worldwide, according to the World Health Organization (WHO), the technology is designed to improve access to fertility care by simplifying procedures that typically require advanced lab infrastructure.

AutoIVF says the system could help make fertility treatments more accessible by removing some of the technical barriers that currently limit availability.

The company is led by chief executive Ravi Kapur PhD, FAIMBE, and backed by a leadership team with more than 200 years of combined experience in reproductive health, microfluidics, and IVF technologies.

“The National Institutes of Health‘s ongoing support through their Small Business Innovation Research Awards has validated the strength of our technology and our rigorous clinical approach. This foundation has enabled us to demonstrate the real-world impact of OvaReady. With this new investment and partnership, we’re excited to accelerate our path to market and explore collaborations that can expand access, scale innovation, and create lasting value across the reproductive health ecosystem,” said Kapur.

Vitrolife’s investment aligns with its goal of building out a full-service fertility platform.

‘This investment and partnership mark another step in our corporate strategy to build an end-to-end platform that connects products and services across the entire IVF workflow. By continuing to automate the IVF process we will enable safe, efficient and effective fertility care,” says Bronwyn Brophy O’Connor, chief executive of the Vitrolife Group.

As part of the deal, Erin Schardt, senior vice president and general manager for North America at Vitrolife, will join AutoIVF’s board of directors.

AutoIVF has positioned OvaReady as a technology that could reduce costs and expand access to treatment, though it has not yet disclosed pricing details.

Based in California, the company has raised more than US$16 million in combined public and private funding, including research grants from the National Institutes of Health’s Small Business Innovation Research programme.

Vitrolife Group, headquartered in Gothenburg, Sweden, employs about 1,100 people and distributes reproductive health products and services in over 125 countries through direct operations and distributor networks.